The incremental cost per unit reduction in Framingham risk score was incorrectly reported as INR 1,26,569 (Int$7105). The correct value is INR 1,265.69 (Int$71.05). This affects the Framingham risk score incremental effectiveness and ICER values in Table 3, and changes in data shown in Table S2.
The cost per percentage increase in optimal cardiac health, reported as INR 1,46,970 (Int$8,251), is at the group level. The per-person cost is INR 178.15 (Int$10.00).
Table 3
Incremental cost and cost-effectiveness of the intervention.
| VARIABLES | INCREMENTAL COST | INCREMENTAL EFFECTIVENESS | ICER | |||
|---|---|---|---|---|---|---|
| AGGREGATE | PER PERSON | AGGREGATE | PER PERSON | AGGREGATE | PER PERSON | |
| Glucose, mg/dl | 25,56,968 (143,545) | 3263.95 (183.23) | –5471 | –6.79904 | –467.37 (26.24) | –480.06(26.95) |
| HbA1c, % | –25,94,418(145,647) | 3304.85(185.53) | –1144.16 | –1.41869 | –2267.53(127.3) | –2329.51(130.8) |
| Total Cholesterol, mg/dl | 25,56,968 (143,545) | 3263.95 (183.23) | –14585 | –18.2615 | –175.31(9.84) | –178.73(10.03) |
| LDL, mg/dl | 25,56,968 (143,545) | 3263.95 (183.23) | –11,750.2 | –14.6113 | –217.61(12.22) | –223.39(12.54) |
| HDL, mg/dl | 25,56,968 (143,545) | 3263.95 (183.23) | 5767.8 | 7.163697 | 443.318(24.89) | 455.62(25.58) |
| Waist Circumference, cm | 22,96,308 (128,912) | 2959.93 (166.17) | –3360.67 | –4.17584 | –683.29(38.36) | –708.82(39.79) |
| BMI, kg/m2 | 22,99,232 (129,076) | 2946.96 (165.44) | –1341.75 | –1.65666 | –1713.6(–96.2) | –1778.85(99.86) |
| Systolic BP, mmHg | 23,11,108 (129,743) | 2943.72 (165.26) | –4701 | –5.80374 | –491.62(–27.6) | –507.21(28.47) |
| Diastolic BP, mmHg | 23,11,108 (129,743) | 2943.72 (165.26) | –2573.5 | –3.17845 | –898.04(–50.41) | –926.15(51.99) |
| Framingham Risk Score, % | 25,56,968 (143,545) | 3263.95 (183.23) | –2059.08 | –2.579 | –1241.80 (69.71) | –1265.69(71.05) |
Table S2
Changes in Clinical Parameters.
| VARIABLES | AGGREGATE CHANGE (UC) | PER-PERSON CHANGE (UC) | AGGREGATE CHANGE (IG) | PER-PERSON CHANGE (IG) |
|---|---|---|---|---|
| Fasting Glucose (mg/dL) | 582 | 0.7106 | –4889 | –6.0884 |
| HbA1c (%) | 270.2 | 0.3303 | –874.0 | –1.0884 |
| Total Cholesterol (mg/dL) | –4043 | –4.9365 | –18628 | –23.198 |
| LDL (mg/dL) | 887.2 | 1.0833 | –10863 | –13.528 |
| HDL (mg/dL) | –785.8 | –0.9595 | 4982 | 6.204 |
| Waist Circumference (cm) | 530.6 | 0.6471 | –2830.1 | –3.529 |
| BMI (kg/m2) | 393.4 | 0.4785 | –948.4 | –1.178 |
| Systolic BP (mmHg) | 952.5 | 1.1588 | –3748.5 | –4.645 |
| Diastolic BP (mmHg) | 465.5 | 0.5663 | –2108 | –2.6121 |
| Framingham Risk Score (%) | –598.5 | –0.7307 | –2657.6 | –3.309 |
Competing Interests
DP and PJ received research grants from the US National Heart Lung and Blood Institute for a work-site-based cardiovascular risk reduction initiative (5R01HL125442-05). PJ also received research grants from the Australian National Health and Medical Research Council (1160283 and 1169766), the World Diabetes Federation (WDF-15–959), the National Institute for Health and Care Research, UK (204871), and the Indian Council of Medical Research for diabetes and hypertension risk reduction interventions. PJ is also a member of the editorial team for the journal but recused themselves from any editorial involvement with this article. All other authors declare no competing interests.